you are here:

Strides Pharma Science Ltd.

BSE: 532531 | NSE: STAR |

Represents Equity.Intra - day transactions are permissible and normal trading is done in this category
Series: EQ | ISIN: INE939A01011 | SECTOR: Pharmaceuticals

BSE Live

Mar 05, 16:00
868.30 1.50 (0.17%)
  • Prev. Close


  • Open Price


  • Bid Price (Qty.)

    857.00 (25)

  • Offer Price (Qty.)

    872.60 (5)

NSE Live

Mar 05, 15:58
867.45 0.85 (0.10%)
  • Prev. Close


  • Open Price


  • Bid Price (Qty.)

    867.45 (3126)

  • Offer Price (Qty.)

    0.00 (0)

Company History - Strides Pharma Science
 -Board approves for the allotment of 210,955 shares of the company at
 Rs.10 each to the share holders of Bombay Drugs & Pharmas Ltd.
 -Zenith Pharmaceuticals Ltd acquires 71% shares through preferential
 issue route.
 -Board approves for the proposal of restructuring its Cram division
 by hiving off into two separate company under the provisions of the
 companies act.
 -Incorporates 'Strides Africa Ltd' at British Virgin Island with an
 authorised capital of US $ 200,000 as 100% wholly owned subsidiary.
 -Board decides to change the name of the company to 'Strides Arcolab
 (FA)' to reflect the change in the business focus and operations.
 -Nominates Mr Francis Pinto as the Director on the Board of the
 -Forges an exclusive co-operation alliance with the South Africa
 based drug manufacturer Aspen Pharmacare, mainly to share the product
 development expertise and quality systems.
 -Concludes the strategic development and manufacturing agreement with
 Sorm Co. Ltd  for long term supply of Generics, OTC and Nutraceutical
 -Changes in the Management:
 Appoints Mr V Hariharan as CFO, Mr Joe Thomas as President, and Mr
 Krishna Kumar Menon as COO.
 -Board approves for the reorganization of subsidiaries of the company
 and for write off of dimunition in value of investments made in
 subsidiaries by the company.
 -Strides inks MoU with Ribbon SRL for Cephalosporin
 -Major Fire occurs in Private Custom Bonded warehouse in Mexico
 -Strides Arcolab Limited has entered into a memorandum of
 understanding with BITS, Pilani for an ``off campus collaborative
 programme''. As part of the partnership, Strides has launched a new
 initiative called STEP (Strides Training and Education Plan) intend
 to offer their employees an opportunity to acquire a MS in Pharma
 Operations & Management while on the job.
 - Enters into an agreement with Mayne Pharma Business Unit of
 Australia based Mayne Group Ltd, to develop and manufacture a range
 of six anti-infective products that Mayne will market and distribute
 in the US and European markets.
 -Strides Arcolab enters into an agreement for private placement
 - Strides Arcolab signs License Agreement with KV Pharma for
 exclusive marketing rights in the United States and Canada for 10 new
 generic drugs
 -Strides acquires sterile manufacturing facility in Poland
 -  Strides Arcolab has got tentative permission from the United
 States Food and Drug Administration (USFDA) for Efavirenz tablets, an
 anti-HIV drug. Efavirenz, is the generic version of Bristol Myers
 Squibb's Sustiva, which helps in preventing the HIV virus from
 - Strides Arcolab receives 2 more NDA approvals from US-FDA.
 - Strides Arcolab Ltd on March 19, 2008 announced its third ANDA
 approval for Fosphenytoin Injection 50mg/mL in 2 ml and 10 ml vials.
 - Strides Arcolab Ltd has informed that Mr. V. S. Iyer has been
 appointed as an Executive Director of the Company.
 -Strides Arcolab Receives US FDA NOD To Commercialize First Sterlite
 -Strides announces First European Approval for Oncology Product
 -Strides Arcolab receives US FDA Nod to Commercialize First Liquid 
 -StridesArcoL Update on acquisition of outstanding minority
 shareholding in Ascent Pharmahealth Limited
 -Strides Arcolab joins the Malaysian Bio-xcell Ecosystem
 -Strides Arcolab Announces US FDA approval for its 'Brazilian Sterile
 -Strides Arcolab receives US FDA approval for Methotrexate Injection
 -Strides Arcolab Announces Health Canada Approval For Tobramycin
 -Strides Arcolab acquires Sterile Formulations facility to expand
 core injectable biz
 -Strides collaborates with Gilead Sciences
 -Strides Arcolab receives ANDA approval from USFDA for Tenofovir
 Disoproxil Fumarate and Emtricitabine Tablet.
 - Strides Arcolab announces US FDA approval for its Italian
 Semi-solids and Oinment facility.
 - Strides announces WHO pre-qualification for Artemether +
 Lumifantrine .
 -StelisBiopharma and Pieris Forge Alliance for Novel Anticalin
 Therapeutics in Ophthalmology.
 -Strides Arcolab - Re-branding Biotech Business as ''Stelis''.
 -Strides Arcolab - Pfenex Inc. and Agila Biotech Private Ltd Announce
 Joint Venture to Develop Biosimilar Products for the Global Market.
 -- Medicines for Malaria Venture announces collaborations with Cipla
 and Strides.
 -Strides Arcolab makes strategic investment in Oncobiologics Inc.,
 - Strides partners with Gilead Sciences Inc, to bring Hepatitis C
 cure to 91 developing countries.
 -Strides Arcolab receives US FDA approval for Buspirone Tablets.
 -Strides Arcolab receives US FDA approval for Calcitriol Softgel.
 -Strides Arcolab acquires 'Raricap' and India Branded Generic
 Business of Bafna.
 -Strides Arcolab to acquire Shasun Pharma in all stock deal.
 -Strides Arcolab Ltd. has entered into an agreement with Fortuna
 Public Relations Pvt. Ltd., Delhi appointing them as Company's Public
 Relations Agenc
 -Strides Arcolab Ltd that it has entered into a licensing agreement
 with Gilead Sciences Inc, 
 -Strides Arcolab Ltd has launched the generic drug Sofosbuvir in
 India  Virso
 -Strides Arcolab gets USFDA nod for Polyethylene Glycol 3350
 -Strides Arcolab gets USFDA nod for HIV treatment drug
 -Strides Arcolab Ltd has approved the merger of Shasun
 Pharmaceuticals Ltd with the company.
 -Strides Arcolab has completed the Rs 1,910-crore acquisition of
 Aspen Pharmacare, Australia. 
 -Strides Arcolab acquires CNS divisions of erstwhile Ranbaxy
 -Strides Arcolab Ltd has changed from its present name Strides
 Arcolab Limited to Strides Shasun Limited
 -Strides Shasun  updates on Acquisition of seven brands from Johnson
 & Johnson.
 -Strides Shasun update on Acquisition of CNS divisions of erstwhile
 -Strides Shasun to acquire a strategic stake in Generic Partners
 Holdings, Australia.
 -Strides Shasun to acquire controlling stake in Universal
 Corporation, Kenya.
 -Strides Shasun receives USFDA Tentative Approval for Efavirenz
 - Strides Shasun announces successful completion of US FDA inspection
 at its Oral Dosage Facility in Bangalore.